Thuja capital portfolio company ArGEN-X raises EUR 9.5M
Thuja Capital's portfolio company ArGEN-X, a research stage biopharmaceutical company, has successfully closed an equity financing round, raising EUR 9.5 million. The financing round is one of the largest in its kind in Europe in the last 12 months.
The deal was co-led by Forbion Capital Partners and Life Sciences Partners (LSP). Christina Takke for Forbion Capital Partners and John de Koning for LSP have joined the arGEN-X Supervisory Board. Other members of the syndicate are KBC Private Equity (Belgium), BioGeneration Ventures (The Netherlands) and existing shareholders Erasmus MC Biomedical Fund and Thuja Capital Healthcare Funds.
ArGEN-X was seed funded in April 2008 by Thuja Capital Healthcare Seed Fund in collaboration with Erasmus MC Biomedical Fund.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.